Edinburgh Molecular Imaging Ltd. (EM Imaging) has signed an exclusive global license for a novel optical imaging agent that could improve the detection of early-stage colorectal cancer.

A recently developed drug was significantly better at detecting recurring prostate cancer in early stages, in research published in the August 2015 issue of The Journal of Nuclear Medicine. In the study, the imaging agent — Ga-68 prostate-specific membrane antigen (Ga-68 PSMA) — used with positron emission tomography and computed tomography (PET/CT), changed management in 44 percent more cases than another widely used agent.

At the National Nuclear Security Administration’s (NNSA) 2015 Mo-99 Topical Meeting, Novation offered its support of efforts to encourage the adoption of processes to create a reliable domestic supply of non-highly enriched uranium (HEU) molybdenum-99 (Mo-99).

Healthcare imaging specialist Barco announced it has received the 2015 Frost & Sullivan Award for best practices in Visionary Innovation Leadership in the medical imaging displays market. The award comes on the heels of the release of the Coronis Uniti display system in 2014.